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Purpose: To assess the impact of mid-treatment parotid gland shrinkage on long term xerostomia during IMRT for
oropharyngeal SCC.
Methods and materials: All patients treated with IMRT at a single Institution from November 2007 to June 2010
and undergoing weekly CT scans were selected. Parotid glands were contoured retrospectively on the mid treatment
CT scan. For each parotid gland, the percent change relative to the planning volume was calculated and combined
as weighted average. Patients were considered to be xerostomic if developed GR2+ dry mouth according to CTCAE
v3.0. Predictors of the time to xerostomia resolution or downgrade to 1 were investigated at both uni- and multivariate
analysis.
Results: 85 patients were selected. With a median follow up of 35.8 months (range: 2.4-62.6 months), the actuarial
rate of xerostomia is 26.2% (SD: 5.3%) and 15.9% (SD: 5.3%) at 2 and 3 yrs, respectively. At multivariate analysis,
mid-treatment shrink along with weighted average mean parotid dose at planning and body mass index are
independent predictors of the time to xerostomia resolution. Patients were pooled in 4 groups based on median
values of both mid-treatment shrink (cut-off: 19.6%) and mean WA parotid pl-D (cut-off: 35.7 Gy). Patients with a
higher than median parotid dose at planning and who showed poor shrinkage at mid treatment are the ones
with the outcome significantly worse (3-yr rate of xerostomia ≈ 50%) than the other three subgroups (3-yr rate of
xerostomia ≈ 10%).
Conclusion: For a given planned dose, patients whose parotids significantly shrink during IMRT are less likely to
be long-term supplemental fluids dependent.
Keywords: Parotid gland, IMRT, ShrinkageIntroduction
Long-term dry mouth is a debilitating side effect of
radiotherapy for head and neck cancer. More than a
decade ago, Eisbruch et al. explored for the first time
the existence of a direct relationship between the dose
received by parotids and salivary output after radiother-
apy [1]. After this early work, many studies investigated
this issue, leading to a quite good consensus around the
parallel behavior of parotids and the value of the mean
dose to predict xerostomia [2]; consequently, this know-
ledge led to limit prospectively the dose to the parotid
glands throughout IMRT. Data from randomized studies
have confirmed the clinical validity of this approach [3].* Correspondence: fiorino.claudio@hsr.it
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unless otherwise stated.However, despite ‘dosimetric’ sparing of the parotids,
20-25% of patients still develop long-term xerostomia.
Whether this reflects a different intrinsic radiosensitivity
among patients, the added damage to other major/minor
glands or the inability to correctly predict for the real dose
delivered to the parotids is unclear.
We and others have shown that the parotid glands
undergo, on average, a ≈ 30% percent reduction in volume
during radiotherapy [4,5] and this, along with their migra-
tion medially towards the high dose region [6], may actu-
ally result in a higher than planned cumulative dose [7].
On the other hand, early parotid gland shrinkage during
treatment has been found to be independently correlated
to the dose at planning [5] and thus volumetric reduction
may just indirectly reflect a higher dose at planning.
Regardless the mechanism, we recently found a correlationtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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acute xerostomia in 24 patients [8], suggesting that mor-
phologic changes may have detectable clinical relevance.
While these data need confirmation in a larger cohort, they
also raise the possibility that early volumetric changes may
be used to predict for late or long term toxicity.
In the present study we investigated the impact, if any,
of parotid gland shrinkage at mid-treatment on long
term xerostomia after accounting for the parotid dose at
planning and other potential confounders.
Materials and methods
Patients and treatment
For the purpose of the present study, that has been
approved by the local IRB, patients treated with defini-
tive IMRT ± chemotherapy for oropharyngeal SCC and
who underwent weekly (KV)CT scans in addition to the
planning CT (pl-CT) as part of an internal QA program
at Johns Hopkins University from November 2007 to
June 2010 were selected [5].
All patients underwent 3 dose level painting IMRT
with 68.25/70 Gy prescribed to macroscopic disease
(CTV1), 63 Gy to microscopic high risk disease (CTV2)
and 58.1 Gy to microscopic low risk disease (CTV3). All
doses were given in 35 fractions over 7 weeks. Each
CTV was expanded by 5 mm to the corresponding PTV.
IMRT was administered with a 9-field step and shoot
technique. Thirty-five patients (41.2%) underwent daily
CBCTs (IGRT). Dose volume objectives were placed
on both primary (brain, brainstem, cord + 4 mm) and
secondary (mandible, parotids and larynx) organs at
risk. For the parotids, the dose volume objective was
set at V30 Gy < 50%. All patients were treated compre-
hensively on both sides of the neck. Parotid glands were
retrospectively contoured on the mid treatment CT
scan under the supervision of the same physician (G.S.)
and blindly to clinical outcome. Patients with parotid
glands grossly infiltrated by tumor were excluded.
Major salivary glands were arbitrarily labeled as H or L
whether they were planned to receive the higher (H) or
lower (L) mean dose within a given patient.
For each parotid gland, the percent change in volume
relative to the planning volume was calculated at the CT
closest to mid-treatment. Each side was entered separ-
ately or as a combined weighted (by the volume at plan-
ning) average. Regarding the mean dose at planning of
major salivary glands, each organ was entered separately
or as combined mean dose. The latter was computed as
the weighted (by the volume at planning) average of the
mean doses to each gland.
Statistics
According to internal guidelines, patients were scheduled
to be seen also in the department of Radiation Oncologyat regular follow up intervals (3, 6, 12, 18, 24, 36, 48 and
60 months after treatment completion).
As previously reported [9], at each follow up examin-
ation, dry mouth/xerostomia was scored and digitally
recorded by one observer (G.S.) according to Common
Terminology Criteria for Adverse Events v 3.0. Grade 1
(GR1) would include patients with dry or thick saliva
without significant dietary alteration; Grade 2 (GR2),
symptomatic patients with significant oral intake alter-
ation (i.e. copious water or other lubricants). Particular
attention was placed to whether or not the patient was
carrying supplemental fluids at the time of the office
examination. Salivary flow was not measured routinely.
The main purpose of the present study is to investigate
the predictive role of parotid gland shrinkage at mid-
treatment along with selected patient-, tumor- and
treatment-related characteristics on the time to xerosto-
mia resolution (GR0) or downgrade from GR2+ to GR1.
This was computed from the end of radiotherapy to the
date of the first visit in which objective and subjective
assessment parameters were consistent with GR0-1 dry
mouth or the last follow up for censored observations
(patients without xerostomia resolution). Observations
obtained after locoregional failure were disregarded, with
the exception of residual disease at complementary neck
dissection. For patients who did not develop GR2+ xer-
ostomia, the time to xerostomia resolution/downgrade
was set at zero. In patients with bouncing scores at sub-
sequent follow ups (i.e. GR2→GR1→GR2), only the
worst/latest score was considered, disregarding earlier
improvements.
Actuarial rates were computed with the Kaplan Meier
method and compared with the log rank test. Covariates
with a p-value lower than 0.2 at univariate analysis were
entered into a Cox proportional hazard ratio at multi-
variate analysis. A backward selection procedure based
on the likelihood ratio test was used to select variables.
Patients were pooled in 4 groups based on median
values of both mid-treatment shrink and mean weighted
average parotid planning dose. All tests were two-sided
and statistical significance was claimed for a p value < 0.05.
All analyses were performed using GraphPad (version 5.0,
GraphPad Software Inc, San Diego, CA) and SPSS (version
17.0, SPSS Inc, Chicago, IL).
Results
The analyzed patient population consists of 85 patients.
Main patient, tumor and treatment characteristics have
been reported previously and are summarized in Table 1
[5]. Briefly, median age was 57.5 years (range: 30–81 yrs)
while median body mass index (BMI) was 28.45 kg/m2
(range: 20.45-41.82 kg/m2). Eighty-two of 85 patients
completed IMRT as prescribed with 3 patients missing
1–2 fractions (total dose: 66–68 Gy). Median overall
Table 1 Selected patient, tumor and treatment
characteristics
Characteristic Stratification # pts %
Sex Male 77 90.6
Female 8 9.4
Primary tumor site Tonsil 37 43.5
Base of tongue 46 54.1
Pharyngeal wall 2 2.4




Smoking at diagnosis No 67 78.8
Yes 18 21.2
Smoking during follow up No 73 85.9
Yes 12 14.1
PEG No 17 20.0
Yes 68 80.0
Px dose to PTV1 68.25 Gy 5 5.9
70 Gy 80 94.1
Chemotherapy Concomitant (Platin-based) 63 74.1
Induction + Concomitant 7 8.2
Cetuximab 5 5.9
None 10 11.8
Table 2 Dosimetric parotid gland data at planning
Median Range
Volume at pl Average 33.1 15.9/59.4
(cc) H 32.6 16.0/58
L 32.9 15.9/63.5
Mean D at pl Weighted avr 35.7 17.5/57.4
(Gy) H 39.9 27.4/70.4
L 33.1 4.5/62.3
Shrinkage at mid tmt Weighted avr 19.6 1.2/52.1
(%) H 21.2 1.8/52.7
L 19.0 0.7/51.6
Abbreviations: pl planning, avr average, D dose, H/L side that receives the
higher (H) or lower (L) mean dose at planning within a given patient.
Figure 1 Actuarial rate of physician-reported GR2+ xerostomia
in the whole group of patients.
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median relative weight change during treatment was
−8.9% (range: +5.6% to −24.7%).
Patients underwent the pre-treatment planning CT at
a median time of 19 days (range: 10–25 days) before
treatment initiation; the median number of fractions
from treatment start to mid-treatment scan were 16
(range: 13–21 fxs) [5].
Dosimetric parotid gland data at planning are summa-
rized in Table 2. Mean submandibular doses at planning
were as follows: median contralateral SMG mean dose
(85 pts), 59.3 Gy (range: 12.8/71.4 Gy); median ipsilateral
SMG mean dose (80 pts), 68.4 Gy (range: 50.0/73.1 Gy);
median weighted average SMG mean dose (80 pts),
63.6 Gy (range: 35.4/71.6 Gy). Median weighted average
combined parotid and submandibular mean dose at
planning was 42.4 Gy (range: 22.7/58.7 Gy). The latter
was closely correlated to the WA parotid (Spearman
rho = 0.88, p < 0.001) rather than the WA SMG (rho =
0.17, p = 0.13) mean dose. Median oral mucosa mean
dose at planning was 53.1 Gy (range: 35.7/69 Gy).
Median follow up is 35.8 months (range: 2.4-62.6
months). Six patients failed locoregionally and 5 more
distantly. Locoregional control at 3 yrs is 90.4 ± 3.9%.The median number of observations per patient is 4
(range: 1–7). All patients developed xerostomia: 8
(9.4%), 61 (71.8%) and 16 (18.8%) patients developed
peak GR1, GR2 and GR3 dry mouth at some point,
respectively. However, xerostomia improved in most
patients with only 23 patients (27.0%) still considered
having GR2+ dry mouth at the date of last follow up.
From an endpoint perspective (GR2+), only 3 patients
(3.5%) had inconsistent findings at consecutive follow
ups (i.e. they were scored as having xerostomia reso-
lution at an earlier follow up but subsequently relapsed
to GR2+ toxicity at a later visit).
The actuarial rate of GR2+ xerostomia is depicted in
Figure 1 with rates of GR2+ xerostomia of 50.7% (SD:
5.5%), 26.2% (5.3%) and 15.9% (5.3%) at 1, 2 and 3 yrs,
respectively.
Regarding the time to xerostomia resolution or down-
grade to GR1, results of univariate analysis are reported in
Table 3. Mid-treatment parotid shrink is weakly correlated
to both BMI (rho = −0.234, p = 0.031) and pl-mean parotid
D (rho = 0.258, p = 0.017). Results of multivariate analysis
are reported in Table 4. Mid-treatment shrink along with
Table 3 Univariate analysis on the time to xerostomia resolution or downgrade to GR1
Covariate Stratification HR 95% CI p value
Age Continuum 1.007 0.980-1.035 0.605
Sex F vs M 0.679 0.243-1.900 0.461
AJCC stage I-III vs IV 1.634 0.912-2.928 0.099
Induction + conc CHT Yes vs No/Cet 0.519 0.162-1-659 0.269
Concomitant CHT Yes vs No/Cet 0.556 0.295-1.050 0.070
Body Mass Index Continuum 0.938 0.885-0.995 0.034
% PG Shrinkage at mid-tmt Continuum 1.028 1.000-1.057 0.046
Smoking at diagnosis Yes vs No 0.912 0.664-1.253 0.572
Smoking during follow up Yes vs No 0.886 0.597-1.315 0.547
H- Mean PG pl-D Continuum 0.962 0.930-0.995 0.023
L- Mean PG pl-D Continuum 0.963 0.927-1.002 0.061
WA mean PG pl-D Continuum 0.943 0.904-0.984 0.007
H- Mean SMG pl-D Continuum 0.943 0.871-1.020 0.142
L- Mean SMG pl-D Continuum 0.992 0.961-1.025 0.647
WA mean SMG pl-D Continuum 0.981 0.935-1.030 0.436
WA mean PG + SMG pl-D Continuum 0.944 0.904-0.987 0.011
Oral mucosa mean D Continuum 0.991 0.951-1.033 0.674
Abbreviations: see Table 2; HR hazard ratio, CI confidence intervals, CHT chemotherapy, pl-D planning dose, F female, M male, PG parotid gland, SMG submandibular
gland, WA weighted average.
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BMI are independent predictors of xerostomia resolution/
downgrade to GR1.
Patients were pooled in 4 groups based on median
values of both mid-treatment shrink (cut-off: 19.6%)
and mean WA parotid pl-D (cut-off: 35.7 Gy). Figure 2
illustrates the time to xerostomia resolution/downgrade
to GR1 by each group, disregarding BMI. Patients with
a higher than median parotid dose at planning and who
showed poor shrinkage at mid treatment are the ones
with the worst outcome (3-yr rate of GR2+ xerosto-
mia ≈ 50%); conversely, despite a higher than median
parotid dose at planning, patients with an average mid
treatment shrink larger than 19.6% had a time to xeros-
tomia resolution/downgrade similar to that of patients
planned to receive a lower mean dose to the parotids
(for both subgroups, 3-yr rate of GR2+ xerostomia
<10%). The difference between patients with high pl-D/
low shrink and each of the other 3 groups is statistically
significant (p < 0.05).Table 4 Multivariate analysis
Covariate HR 95%CI p value
Lower Upper
Body Mass Index 0.932 0.875 0.992 0.027
% PG Shrinkage at mid-tmt 1.034 1.004 1.064 0.024
WA mean PG pl-D 0.927 0.886 0.971 0.001
Abbreviations: see Table 3.Discussion
We have previously shown that mid-treatment parotid
shrinkage is independently correlated to the planning
mean dose [5]. The present paper shows that, once the
mean dose at planning is accounted for, the percent
shrinkage of parotids at mid-treatment predicts for the
time to GR0-1 xerostomia. Therefore, as illustrated in
Figure 2, mid treatment shrink helps to stratify patients
with a higher than median parotid dose at planning into
those at low and high risk of long-term GR2+ xerostomia.
This finding is somewhat unexpected and counterintu-
itive. Parotid shrinkage during treatment has been asso-
ciated with a larger than planned delivered dose to the
parotids due to their migration medially towards the
high dose region [6]. Therefore, one would expect that
the more the parotids shrink during treatment, the
higher is the probability of long term side effects due to
their overdosing compared to planning. On the other
hand, in one study on 10 patients which assessed the
cumulative dose received by the parotids, a higher than
planned dose was reported only for a minority of
patients [7]. Moreover, recent data shows that, on aver-
age, the extra mean dose delivered is modest (<4 Gy,
overall) and, most importantly, other factors such as
set-up errors are likely to have a higher impact on the
final dose than parotid shrinkage [10].
In a previous study focusing on a small subset of the
patients considered here (N = 24), we had found a positive
correlation between the daily rate of both density and
Figure 2 Actuarial rate of physician-reported GR2+ xerostomia by both mid-treatment combined parotid gland shrinkage and mean
weighted average parotid dose at planning. Low/high represent values below/above median values of 19.6% and 35.7Gy for mid-treatment
shrinkage and mean combo parotid dose, respectively.
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and mean acute xerostomia scores according to CTCAE
v3.0 [8]. Patients with rapidly shrinking parotids during
the earlier part of treatment were those at higher risk of
developing acute xerostomia. However, due to the limited
number of patients, we could not tease out the effects of
parotid shrinkage and mean parotid dose at planning
which we had previously found to be directly correlated
[5]. In the present study the higher number of patients
included (N = 85) allowed us to analyze the effect of par-
otid shrinkage on long term xerostomia while ‘correcting’
for the dose at planning. At later time points and after
accounting for the mean parotid dose, we found that the
opposite is true: shrinkage during the first part of treat-
ment predicts for a higher rate of long-term recovery.
Acinar cell loss is the main cause of functional damage
in human salivary glands after RT and we previously
found that parotid shrinkage during treatment is accom-
panied by a decrease in tissue density consistent with a
relative increase in fat over glandular tissue [11,12].
Parotids that show modest volumetric changes earlier
during treatment are at higher risk of persistent damage,
suggesting that their acinar component is limited to
begin with. Therefore, even if a given dose of radiation
would kill the same fraction of cells, the absolute damage
would be higher for those glands with a lower baseline
acinar component. On the other hand, there is a clear
possibility that more sensitive patients (i.e.: showing
larger shrinkage) could experience a faster replacement
of the acinar cells due to the activation of stem cells, ef-
ficiently recovering the gland functionality in the longrun. In any case, our results are hypothesis generating
and a validation prospective clinical study is underway.
If confirmed, they open the possibility to have an extra
tool (besides the planning dose) to identify patients at
risk of persistent GR2+ xerostomia. It is also interesting
to note that the present data also tend to reduce the
clinical impact of adaptive strategies that aim at keeping
the dose to the parotids stable during the course of
IMRT, since patients who are supposed to benefit more
from such strategies, those with significant parotid shrink-
age, are the ones with the higher functional recovery after
a non-adapted treatment course.
Few other aspects of the present paper deserve some
comments. To our knowledge this is the first study that
included in the analysis of xerostomia also BMI. The
present data show that the time to recovery of xerosto-
mia in patients who are overweight is longer than in
patients who are not overweight and this may be related
to the well know observation of a higher rate of dry
mouth of patients with BMI > 30 Kg/m2 [13].
We acknowledge that xerostomia is not only due to
parotid gland irradiation [14], though in the present
study the dose to both the submandibular and minor
salivary glands (oral mucosa dose) did not show inde-
pendent predictive value on xerostomia suggesting that
their role is probably marginal relatively to the endpoint
considered here. Of note, contrary to Ortholan et al.
[15], we found a higher predictive value when the mean
parotid dose on both sides was combined over consider-
ing each side separately. Regarding the endpoint, it is
well known that physician-reported outcomes do not
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being an interpretation of the latter ones. However, it
should be noted that CTCAE criteria for xerostomia in-
corporate both subjective and objective assessments.
According to Common Toxicity Criteria Adverse Event
v 3.0+, what differentiates between grade 1 and 2 saliv-
ary gland toxicity is whether ‘significant oral intake
alterations’ are present. These include ‘copious water’
and ‘other lubricants’ as well as dietary alterations (soft
diet, moist foods) though the latter ones are usually
related more to dysphagia than xerostomia.
Conclusion
In conclusion, we provide evidence that, for a given
radiation dose at planning, patients whose parotids
significantly shrink during IMRT for oropharyngeal
cancer are less likely to be dependent from supplemen-
tal fluids at 1 and 2 yrs after treatment. This finding
potentially provides a novel tool to identify patients
at risk in a timely way during treatment. Prospective
validation is warranted and underway.
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